EMGALITY® IS THE

ONLY CGRP ANTIBODY FDA APPROVED

WITH SPECIFIC DOSES FOR BOTH MIGRAINE AND EPISODIC CLUSTER HEADACHE[1,2]

EPISODIC AND CHRONIC MIGRAINE[1]

- **Method of administration:** Pen or prefilled syringe
- **Monthly dosing strength:** 120 mg

Month 1
2 injections
120 mg + 120 mg

240 mg

Subsequent Months
1 injection per month
120 mg

120 mg

Recommended dosing for Emgality—no titration required[1a]

LOADING DOSE[1]:

- Month 1: **240 mg** (2 consecutive SC injections of 120 mg each) once as a loading dose
- 2 packages with the same NDC must be dispensed when a loading dose is prescribed

SUBSEQUENT MONTHLY DOSE[1]:

- Subsequent months: **120 mg** SC injection once per month

EPISODIC CLUSTER HEADACHE[1]

- **Method of administration:** Prefilled syringe
- **Monthly dosing strength:** 300 mg

1 Dose
3 injections
100 mg + 100 mg + 100 mg

300 mg

Recommended dosing for Emgality during an active cluster period—no titration required[1a]

RECOMMENDED DOSING[1]:

- **300 mg** administered as 3 consecutive SC injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period
  - 300 mg dose; this comes in 3 x 100 mg prefilled syringes
  - These 3 syringes are administered subcutaneously, one after another
- Patients begin treatment at the onset of a cluster period
- Patients take this **300 mg** dose every month until their cluster period ends

[a]The Emgality Pen and prefilled syringe needles are 27 gauge x 1/2 inch.[3,4]
CGRP=calcitonin gene-related peptide; SC=subcutaneous.

INDICATIONS

Emgality is a calcitonin gene-related peptide antagonist indicated in adults for the preventive treatment of migraine and for the treatment of episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Please see Important Safety Information on the following page. See Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

Emgality® (galcanezumab-gnlm)
120 mg injection/300 mg injection

MORE IS POSSIBLE

HOW TO LOCATE AND PRESCRIBE EMGALITY USING AN EMR SYSTEM

Search for "Emgality"

EMR

In the EMR system, select the formulation for your patient's diagnosis[1]:

Emgality Pen 120 mg/mL SC injection	NDC 0002-1436-11	**Quantity:** 1 per box
Emgality Syringe 120 mg/mL SC injection	NDC 0002-2377-11	**Quantity:** 1 per box
Emgality Syringe 100 mg/mL SC injection	NDC 0002-3115-09	**Quantity:** 3 per box

Rx

Prescribe the appropriate dose for your patient:

Emgality 120 mg for migraine

Loading Dose

(Use only if the patient does not begin treatment with a Loading Dose Kit [sample][a] in the office)

Dispense: 2 pens or syringes at once with 0 refills

Maintenance Dose

(Use for all patients with migraine)

Dispense: 1 pen or syringe once monthly with 10 refills

Emgality 300 mg for episodic cluster headache

Recommended Dosing

Sig:
3 SC injections once monthly during an active cluster period

Dispense:
(3) 100 mg prefilled syringes with 3 refills

[a]Loading Dose Kits (samples) are intended to establish safety and efficacy for a patient.

EMR=Electronic Medical Record.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 10DEC2019

References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. **2.** Data on File. Lilly USA, LLC. DOF-GZ-US-0085. **3.** Data on File. Lilly USA, LLC. DOF-GZ-US-0060. **4.** Data on File. Lilly USA, LLC. DOF-GZ-US-0071.

Emgality® (galcanezumab-gnlm) 120 mg injection/300 mg injection

MORE IS POSSIBLE